J Clin Psychiatry

Narcolepsy med safely and effectively treats ADHD

October 23, 2023

Solriamfetol may be a novel and effective treatment for the management of ADHD in adults, although further replication in larger trials is required.

• 60 adults with ADHD participated in this remotely conducted, randomized, double-blind, six-week dose-optimization trial of 75 or 150 mg of solriamfetol.
• Solriamfetol was well tolerated, with no significant effect on mean heart rate, systolic BP, or diastolic BP.
• There was no statistically significant treatment effect on the occurrence of adverse events. Compared to the placebo group, solriamfetol recipients experienced adverse events at a rate of at least 10 percentage points higher in the categories of decreased appetite, headache, GI, insomnia, increased energy, CV, and neurologic.
• At the end of the study, a significantly greater proportion of individuals in the treatment group met the a priori-defined treatment response (Clinical Global Impressions scale score indicating much or very much improved and Adult ADHD Investigator Symptom Rating Scale [AISRS] score reduced ≥25%: 45% vs. 6.9%, P = .0020). 
• Greater improvement in total AISRS scores by weeks 3 through 6 was also observed for those treated with solriamfetol (P = .0012).
• Significantly more solriamfetol-treated adults than placebo-treated adults had 0.5-standard deviation improvement in T-score on the BRIEF-A Global Executive Composite (P = .0173); those treated with solriamfetol also had greater mean change in GAF score (-4.8 vs -0.3, P = .0006) and greater mean modified Adult ADHD Self-Report Scale (MASRS) total score change (P = .0047; effect size = 1.23).

Source:

Surman CBH, et al. (2023, October 9). J Clin Psychiatry. Solriamfetol for Attention-Deficit/Hyperactivity Disorder in Adults: A Double-Blind Placebo-Controlled Pilot Study. https://pubmed.ncbi.nlm.nih.gov/37819836/